Pro Pharmaceuticals Group (Australia)

propg.com.au

Pro Pharmaceuticals Group, a specialty pharmaceutical company, focuses on sourcing and licencing products to meet medical needs. Over the last 3 years we have grown our customer base, products and suppliers. Pro Pharmaceuticals Group is a privately owned company was founded in 2015 and is headquartered in Melbourne, Australia.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BUSINESS INSIGHTS, VIEWS AND ANALYSIS

MIRION TECHNOLOGIES TO DIVEST BIODEX PHYSICAL MEDICINE

Biodex Medical Systems | November 30, 2022

news image

Mirion Technologies, Inc. announced that it has entered into a definitive agreement to sell the physical medicine assets of Biodex Medical Systems, Inc. to Salona Global Medical Device Corporation for $5 million in cash at closing and up to an additional $3 million in deferred cash payments. The deferred cash payments are contingent on the performance of the assets during the 12-month period following closing. The assets generated approximately $18 million in revenue with estimated gross margins...

Read More

PHARMA TECH

FORESEE PHARMACEUTICALS AND TRPHARM ANNOUNCE LICENSE AND CO-DEVELOPMENT AGREEMENT

Foresee Pharmaceuticals Co., Ltd | February 24, 2022

news image

Foresee Pharmaceuticals Co., Ltd. a Taiwan and US-based biopharmaceutical company and TRPharm, a leading Turkish healthcare company, announced today that they have entered into an exclusive license agreement for the co-development and commercialisation in Turkey and certain MENA countries of Foresee's FP-045 program, an oral allosteric Aldehyde Dehydrogenase 2 (ALDH2) activator for the treatment of Fanconi Anemia and other rare and severe diseases. Under the terms of this partnership, Forese...

Read More

PHARMA TECH

PHARMAJET PARTNER ZYDUS CADILA ANNOUNCES COVID-19 VACCINE EXPANSION PLAN TO MULTIPLE COUNTRIES WITH KOREAN FIRM

PharmaJet | January 05, 2022

news image

PharmaJet®, the maker of innovative, needle-free injection technology, announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine in Korea. The plan is to manufacture 80+ million doses of the ZyCoV-D vaccine, which was recently granted emergency use approval by India’s national regulatory agency for those aged 12 years and above. The vaccine will be manufactured in Korea and exported to several lower-middle income...

Read More

PHARMA TECH

IXENSOR RECEIVES STRATEGIC INVESTMENT FROM ROHTO PHARMACEUTICAL WITH A SEPARATE TECHNOLOGY LICENSING AGREEMENT

iXensor | April 28, 2022

news image

iXensor, the pioneer of mobile health, announced that Rohto Pharmaceutical Co., Ltd, a multinational pharmaceutical corporation headquartered in Japan, has become the new strategic partner and shareholder. iXensor received Rohto Pharmaceutical's strategic investment to expand its mobile health business globally and accelerate its PixoTech® platform licensing business. Building on this strategic partnership, Rohto Pharmaceutical will deploy iXensor's patented PixoTech&r...

Read More
news image

BUSINESS INSIGHTS, VIEWS AND ANALYSIS

MIRION TECHNOLOGIES TO DIVEST BIODEX PHYSICAL MEDICINE

Biodex Medical Systems | November 30, 2022

Mirion Technologies, Inc. announced that it has entered into a definitive agreement to sell the physical medicine assets of Biodex Medical Systems, Inc. to Salona Global Medical Device Corporation for $5 million in cash at closing and up to an additional $3 million in deferred cash payments. The deferred cash payments are contingent on the performance of the assets during the 12-month period following closing. The assets generated approximately $18 million in revenue with estimated gross margins...

Read More
news image

PHARMA TECH

FORESEE PHARMACEUTICALS AND TRPHARM ANNOUNCE LICENSE AND CO-DEVELOPMENT AGREEMENT

Foresee Pharmaceuticals Co., Ltd | February 24, 2022

Foresee Pharmaceuticals Co., Ltd. a Taiwan and US-based biopharmaceutical company and TRPharm, a leading Turkish healthcare company, announced today that they have entered into an exclusive license agreement for the co-development and commercialisation in Turkey and certain MENA countries of Foresee's FP-045 program, an oral allosteric Aldehyde Dehydrogenase 2 (ALDH2) activator for the treatment of Fanconi Anemia and other rare and severe diseases. Under the terms of this partnership, Forese...

Read More
news image

PHARMA TECH

PHARMAJET PARTNER ZYDUS CADILA ANNOUNCES COVID-19 VACCINE EXPANSION PLAN TO MULTIPLE COUNTRIES WITH KOREAN FIRM

PharmaJet | January 05, 2022

PharmaJet®, the maker of innovative, needle-free injection technology, announced that its partner Zydus Cadila, is partnering with Enzychem Lifesciences to manufacture their COVID-19 plasmid DNA vaccine in Korea. The plan is to manufacture 80+ million doses of the ZyCoV-D vaccine, which was recently granted emergency use approval by India’s national regulatory agency for those aged 12 years and above. The vaccine will be manufactured in Korea and exported to several lower-middle income...

Read More
news image

PHARMA TECH

IXENSOR RECEIVES STRATEGIC INVESTMENT FROM ROHTO PHARMACEUTICAL WITH A SEPARATE TECHNOLOGY LICENSING AGREEMENT

iXensor | April 28, 2022

iXensor, the pioneer of mobile health, announced that Rohto Pharmaceutical Co., Ltd, a multinational pharmaceutical corporation headquartered in Japan, has become the new strategic partner and shareholder. iXensor received Rohto Pharmaceutical's strategic investment to expand its mobile health business globally and accelerate its PixoTech® platform licensing business. Building on this strategic partnership, Rohto Pharmaceutical will deploy iXensor's patented PixoTech&r...

Read More